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Abstract
The Global Programme to Eliminate Lymphatic Filariasis (GPELF) has two major goals: to interrupt
transmission of the parasite and to provide care for those who suffer the devastating clinical
manifestations of the disease (morbidity control). This latter goal addresses three filariasis-related
conditions: acute inflammatory episodes; lymphoedema; and hydrocele. Research during the last
decade has confirmed the importance of bacteria as a cause of acute inflammatory episodes in
filariasis-endemic areas, known as acute dermatolymphangioadenitis (ADLA). Current
lymphoedema management strategies are based on the central role of ADLA as a trigger for
lymphoedema progression. Simple intervention packages are in use that have resulted in dramatic
reductions in ADLA rates, a lower prevalence of chronic inflammatory cells in the dermis and
subdermis, and improvement in quality of life. During the past decade, the socioeconomic impact
of ADLA and lymphoedema in filariasis-endemic areas has received increasing attention. Numerous
operational research questions remain to be answered regarding how best to optimize, scale up,
monitor, and evaluate lymphoedema management programmes. Of the clinical manifestations
targeted by the GPELF, hydrocele has been the focus of the least attention. Basic information is
lacking on the effectiveness and complications of hydrocele surgery and risk of post-operative
hydrocele recurrence in filariasis-endemic areas. Data on the impact of mass administration of
antifilarial drugs on filarial morbidity are inconsistent. Several studies report reductions in acute
inflammatory episodes, lymphoedema, and/or hydrocele following mass drug administration, but
other studies report no such association. Assessing the public health impact of mass treatment with
antifilarial drugs is important for programme advocacy and morbidity control strategies. Thus,
although our knowledge of filariasis-related morbidity and its treatment has expanded in recent
years, much work remains to be done to address the needs of more than 40 million persons who
suffer worldwide from these conditions.
Background
Lymphatic filariasis causes a wide range of clinical signs
and symptoms, including lymphoedema, hydrocele,
lymph scrotum, chyluria, tropical pulmonary eosi-
nophilia (TPE), adenopathy, haematuria, and various
manifestations of worms in ectopic sites [1], among oth-
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ers. A major goal of the Global Programme to Eliminate
Lymphatic Filariasis (GPELF) is to provide basic care for
persons who suffer from the major forms of filariasis-
related morbidity, both acute (inflammatory episodes)
and chronic (lymphoedema and hydrocele). The objec-
tives of this review are to summarize the scientific basis for
morbidity management strategies that have been adopted
by the GPELF and to identify priorities for research. Other
manifestations of lymphatic filariasis (e.g. chyluria) are
not addressed, not because these conditions lack public
health significance, but because no coordinated public
health approach to address them has been established.
Our understanding of lymphatic filariasis morbidity has
evolved considerably during the last 20 years [2-5], and
this new understanding has led to the current strategies for
morbidity management. The clinical manifestations and
factors leading to progression of so-called 'filarial lym-
phoedema' are similar, if not identical, to those for lym-
phoedema in non-filariasis-endemic areas. Indeed, given
the absence of a diagnostic marker for 'filarial lym-
phoedema', as well as its multifactorial aetiology [4],
some have argued that the use of this term should be
avoided. The literature on management of lymphoedema
in filariasis-endemic areas is relatively limited; considera-
bly more is known about the pathogenesis, clinical man-
agement, and psychosocial impact of 'non-filarial'
lymphoedema in Europe, Australia, and North America.
Although it is outside the scope of this document to sys-
tematically review the literature on lymphoedema and
hydrocele from non-endemic areas, we will refer to this
literature in passing.
This review is divided into three sections corresponding to
the three major clinical manifestations to be addressed:
acute inflammatory episodes, lymphoedema, and
hydrocele. For each of these clinical entities, the available
data are reviewed for the following topics: pathogenesis,
epidemiology, economic and social impact, and treat-
ment. A fourth section addresses the impact of mass treat-
ment with antifilarial drugs on all three forms of
morbidity.
Methods
For the first three sections of the paper, we searched the
entire PubMed database at the National Institutes of
Health through November 19, 2006 using the keywords
filariasis, lymphangitis, adenolymphangitis, lym-
phoedema, and hydrocele and then reviewed these refer-
ences for relevance to this review. We also included
relevant reports from the World Health Organisation
(WHO), articles known to us to be in press in peer-
reviewed journals, unpublished academic theses, and
abstracts published in proceedings of meetings of the Brit-
ish Association of Dermatologists and the American Soci-
ety of Tropical Medicine and Hygiene. For the fourth
section of the paper, we searched on the keywords diethyl-
carbamazine (DEC), ivermectin, albendazole, and
selected all papers that 1) described clinical trials or mass
treatment with these drugs for lymphatic filariasis, and 2)
included outcomes of hydrocele, lymphoedema, or acute
inflammatory episodes. We also included clinical and
mass drug trials that had been published before PubMed
was established, which we identified from citations and
reviews of the earlier literature on DEC in lymphatic
filariasis.
Acute inflammatory episodes (acute attacks)
The aetiology of acute inflammatory episodes in lym-
phatic filariasis has long been a subject of debate and con-
fusion. Indeed, a variety of terms have been used in the
literature to describe them, including 'adenolymphangitis
(ADL)', 'acute attack', 'filarial attack', and 'endemic lym-
phangitis', among others [6]. As early as the 1920s, some
scientists argued that bacterial infections were the primary
cause of 'filarial' lymphangitis [7-9]. In 1924, the British
Filariasis Commission went so far as to state that "all the
pathological manifestations" of lymphatic filariasis were
caused by secondary bacterial infections [10]. During
World War II, clinical and pathologic studies of soldiers
with adenolymphangitis and other early clinical manifes-
tations demonstrated the importance of Wuchereria ban-
crofti  adult worms or 4th-stage larvae [11]. The debate
continued after World War II, when the role of the
immune system in triggering adenolymphangitis, as well
as other forms of filarial pathology, was emphasized [12].
One of the major factors contributing both to the debate
and the confusion during the latter half of the 20th century
was the relative lack of emphasis on careful clinical obser-
vation and case definitions. In 1999, Gerusa Dreyer and
colleagues, working in Brazil, defined two distinct clinical
syndromes: acute filarial lymphangitis (AFL), caused by
death of the adult worm, and acute dermatolym-
phangioadenitis (ADLA), associated with secondary bac-
terial infection [13]. AFL is characterized by lymphangitis
that progresses distally or in a 'retrograde' fashion along
the lymphatic vessel, producing a palpable 'cord'. Rarely,
AFL is accompanied by mild fever, headache, and malaise.
Distal lymphoedema may occur, but is usually mild and
reversible, i.e. self-limited. In contrast, ADLA (a term first
used by Olszewski) [14] develops in a reticular or circum-
ferential pattern, and is clinically similar to erysipelas or
cellulitis. Symptoms of local pain and swelling, as well as
fever and chills, are present. In filariasis-endemic areas,
ADLA occurs much more commonly than AFL [13].
Although there is general agreement on the two clinical
syndromes as described by Dreyer et al., it has also been
suggested that exposure to 3rd-stage filarial larvae causesFilaria Journal 2007, 6:2 http://www.filariajournal.com/content/6/1/2
Page 3 of 19
(page number not for citation purposes)
lymphangitis and triggers the onset or progression of lym-
phoedema. A role for 3rd or 4th-stage larvae in lymphangi-
tis or lymphoedema is supported by animal studies,
experimental infections [15], reports of disease in individ-
ual patients travelling from non-endemic areas [16], and
epidemiologic observations that associate incidence of
acute adenolymphangitis with filarial transmission inten-
sity [17,18]. However, a case definition has not been
established for larva-associated lymphangitis that distin-
guishes it from AFL or ADLA; this makes epidemiological
study difficult. Additional work is needed to clarify the
incidence, possible mechanisms, and clinical expression
of larva-associated filarial lymphangitis and to assess its
public health importance in filariasis-endemic areas.
Recent speculation also has focused on a potential role for
Wolbachia  in the pathogenesis of filaria-related disease
[19,20]. Lammie and colleagues have suggested that the
pathogenesis of disease in lymphatic filariasis is multifac-
torial, and have proposed a model that involves the
immune system and also allows for a variety of possible
causes [3].
Limited attention has been paid to the differences in
pathogenesis and clinical manifestations between brugian
and bancroftian filariasis. Obvious differences have been
noted, such as the absence of male urogenital involve-
ment and chyluria and the much more frequent occur-
rence of abscesses at the site of lymph nodes in brugian
filariasis. However, the reasons for these differences are
poorly understood.
Acute dermatolymphangioadenitis
Pathogenesis
Evidence for a bacterial aetiology of ADLA in filariasis-
endemic areas comes from the distinctive clinical signs
and symptoms, isolation of bacteria at the time of the
acute episode, and changes in antibody titres between
acute and convalescent serum specimens [21-31]. In
India, the bacteria most frequently associated with ADLA
are Group A Streptococcus. Other bacteria are often found
in cultures, including those that are usually regarded as
non-pathogenic [22,24,28].
Available evidence indicates that the immune system may
amplify or modulate ADLA. The relative infrequency with
which bacteria are isolated from patients with ADLA
[22,29,32], as well as from persons with cellulitis in areas
not endemic for lymphatic filariasis [33,34], suggests a
role for inflammatory mediators [33-35], perhaps even in
the absence of bacteria.
Little has been published on the antimicrobial sensitivity
of bacteria isolated from persons with ADLA in filariasis-
endemic areas. Available experience suggests that the
organisms most commonly involved are sensitive to pen-
icillin; thus, penicillin is usually recommended for treat-
ment [36,37].
Clinical descriptions of ADLA in filariasis-endemic areas
are remarkably similar to those of erysipelas and cellulitis,
about which much has been written in the dermatologic
literature [38]. Group A Streptococcus is the classical causa-
tive organism for erysipelas, and lymphoedema is a well-
recognized risk factor for erysipelas and cellulitis in areas
not endemic for lymphatic filariasis [35].
Epidemiology
During the early 1990s, the Special Programme for
Research and Training in Tropical Diseases (TDR) spon-
sored a series of population-based studies on the inci-
dence of 'acute attacks' among the general population in
filariasis-endemic areas. The case definition – localized
pain, lymphadenitis and/or lymphangitis and/or cellulitis
and local warmth, with or without systemic manifesta-
tions of fever, nausea, and vomiting (in some studies, last-
ing for at least three days) – is consistent with ADLA. In
these studies, the overall incidence of ADLA ranged from
33 per 1000 per year to 97 per 1000 per year [39-41]. A
study from Papua New Guinea, which found an incidence
of 31 attacks per 1000 population per year, included only
cases with fever [42]. One study in an area endemic for
Brugia malayi, which also included only cases with fever,
found an incidence of 371 episodes per 1000 people per
year [43]. Taken as a group, these studies indicate that the
rate of ADLA is higher in persons with chronic disease,
principally lymphoedema. Among patients in filariasis-
endemic areas, the mean annual reported incidence of
ADLA ranges from 1.5 to more than 7 episodes per patient
[21,32,41,44-51] (Table 1).
The duration of ADLA, primarily based on patient self-
reporting, ranges from 1 to 16 days [21,32,39-
46,48,49,51,52] (Table 1). Recurrent ADLA episodes
result in significant short-term disability, and are of much
greater concern to patients than is lymphoedema per se
[53]. Studies in Ghana indicate that patients with ADLA
are incapacitated for 3 of the 5.1 days of ADLA duration
[40]; in Tanzania, patients are incapacitated for 3.7 of the
8.6 days of ADLA [39]. In India, total disability from
ADLA lasted no more than 3 days in an area with brugian
filariasis [43]. However, preliminary data from Haiti [44]
and Togo [49] suggest that the number of workdays lost
may exceed the duration of the acute ADLA episode itself.
Among persons with lymphoedema, risk factors for ADLA
include increasing patient age [39-41], poor hygiene [54],
and illiteracy [47]. Gender, lymphoedema severity, and
the presence of entry lesions are additional risk factors.
Females tend to experience higher rates than males,Filaria Journal 2007, 6:2 http://www.filariajournal.com/content/6/1/2
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although exceptions have been noted [41]. The relation-
ship between lymphoedema stage and incidence of ADLA
is not consistent among all studies. It is complicated, in
part, by the use of different systems to stage lym-
phoedema. Most studies show a positive association
between lymphoedema stage and observed or patient-
reported incidence of ADLA [6,13,32,55-58]. However,
other studies – all of which relied on patient recall of
ADLA incidence – found no such association
[39,40,44,45]. Data from Brazil, India, and Guyana indi-
cate that the presence [54] and number [50,59] of inter-
digital skin lesions are remarkably strong risk factors for
ADLA.
The epidemiologic association between ADLA frequency
and stage, as well as extensive clinical experience from
both filariasis-endemic and non-endemic areas, strongly
suggest that ADLA episodes are a major – likely the most
important – factor in lymphoedema progression, particu-
larly in filariasis-endemic areas.
Economic and psychosocial impact
Cost
Studies from India, Ghana and Haiti indicate that ADLA
treatment costs to patients range from US$ 0.25 to US$
1.62 per episode, as much as two days' wages [44,45,60-
63]. In Sri Lanka, Chandrasena reported costs of US$ 7.38
per episode for care from private practitioners, although
most patients received free treatment at government clin-
ics [64]. These costs included direct costs of treatment,
including self-medication, as well as travel. Two studies
also included costs of food and accommodation [45,61].
In all cases, except for consultations with herbalists in
Haiti, patients seeking care from health centres or private
providers spent more money than those seeking care from
traditional practitioners, primarily because these provid-
ers had higher consultation charges. In addition, payment
was often provided in-kind when care was given by mem-
bers of the extended family or traditional practitioners. At
the upper end of the spectrum, Kron et al. calculated costs
for personal expenses in the Philippines as high as US$ 25
per ADLA episode, excluding lost wages [52].
Productivity
Much of the burden of ADLA comes not from treatment
costs, but from indirect costs due to lost productivity.
ADLA episodes significantly affect patients' abilities to
carry out both economic (farming, market activities,
building) and domestic (household chores, cooking, tak-
ing care of children) activities [39,40,43,44,53,64,65].
Table 1: Incidence and duration of acute dermatolymphangioadenitis (ADLA) in filariasis-endemic areas.
Study Annual incidence of 
ADLA in general 
population (per 1000)
Annual incidence of 
ADLA in 'patients' 
(per patient)
Mean duration of 
ADLA episode (days)
Study site Notes
Bancroftian filariasis
Addiss 1999 [47] -- 2.1^ -- Haiti
Alexander 1999 [42] 31 -- 16 Papua New Guinea Only cases with fever and 
ADLA in lower limb
Babu 2005 [48] 85.0 1.6† 3.9 Orissa, India
Gasarasi 2000 [39] 33 -- 8.6 Tanzania
Gyapong 1996 [40] 95.9 -- 5.1 Ghana
Kanda 2004 [44] -- 1.5^ 10.6 Haiti
Krishnamoorthy 1999 
[45]
-- 6.4‡ 4.1 Tamil Nadu, India
Kron 2000 [52] -- -- 4.5 Philippines
Mathieu 2005 [49] -- 2.3^ 7.3 Togo
McPherson 2006 [50] -- 1.6^ -- Guyana
Pani 1995 [21] -- 4.2^ 4.1 Tamil Nadu, India
Ramaiah 1996 [41] 96.5 1.8† 3.6 Tamil Nadu, India
Sabesen 1992 [46] 49.8 6.0^ 3.9 Tamil Nadu, India
Brugian filariasis
Pani 1989 [51] -- 4.9^
7.6^
4.9
5.8
Kerala, India Stage 1 oedema
Stage 2 oedema
Rao 1982 [43] 371* -- 1.4 Kerala, India Only cases with fever
Sabesen 1992 [46] 41.4 5.4 4.9 Kerala, India
Suma 2002 [32] -- 4.7^ -- Kerala, India Restricted to patients 
with ≥ 2 ADLA episodes.
^Lymphoedema patients only
‡ Lymphoedema and hydrocele patients
† Among persons with one or more ADLA episodes in 1-year observation period
*Calculated from 7 month follow-upFilaria Journal 2007, 6:2 http://www.filariajournal.com/content/6/1/2
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ADLA episodes are more disabling than other febrile ill-
nesses [61,66]. This incapacitation results in productivity
losses; studies in India and Tanzania showed that patients
with ADLA spent an average of 2.7–3.6 hours less per day
on economic activities than controls [39,60,63,66].
Studies indicate that ADLA episodes reduced potential
community labour supply in Ghana by 0.79% [61] and in
Indian communities by approximately 0.1% [63,66].
While these figures represent a much smaller loss than
that from chronic filarial disease (7% of potential labour
lost), they do not adequately capture the impact of ADLA
at the level of the household. Household-level effects,
including time lost from work and school for caregivers,
have not been studied in detail.
Even with these modest estimates, the productivity lost
due to ADLA represents a significant loss of potential
income. Sabesan estimated that US$ 160000 per year is
lost to ADLA among persons with lymphatic filariasis in
Pondicherry, India [46], while other studies in India esti-
mate a national figure of US$ 60–85 million lost per year
[45,67]. Kron estimated that US$ 38 million is lost annu-
ally due to ADLA in the Philippines [52].
Quality of life
Several studies have reported a strong negative effect of
ADLA on quality of life [53,68-73]. A study of patients at
a filariasis clinic in Haiti found that ADLA affected several
quality of life indicators, including how much one thinks
about the disease and the ability to work [53]. A qualita-
tive study in the Dominican Republic found that the great-
est physical and psychological distress occurs during
ADLA, regardless of stage of lymphoedema (B. Person,
personal communication). Ninety-six per cent of women
interviewed in this study described distress not only from
the pain and disability caused during the ADLA episode,
but also from anticipation of future episodes. A study of
the effect of lymphatic filariasis on schoolchildren in
India found that ADLA led to frequent absenteeism and
impaired performance [68].
In another recent study, patients in India ranked ADLA
higher than lymphoedema and hydrocele in terms of
severity, with an average severity score of 25–27 on a scale
of 0–28. Patients also cited 'very severe problems' in the
domains of mobility, self-care, usual activities, pain, anx-
iety/depression and social participation on an extended
EuroQol scaling system [69]. They reported curtailing
their activities and interactions with others in an attempt
to prevent future ADLA attacks from occurring. Other
studies have noted the pain, restrictions and dependency
that result from ALDA episodes, but have not translated
this into standard quality-of-life indicators [71,72].
Health-seeking behaviour
Studies in India found that 49%–98% of lymphoedema
patients sought treatment for ADLA during the previous
6–12 months, either by consulting government or private
health personnel or self treating. Patients in urban areas
were more likely to seek treatment [45,60,62,63]. In a
study in rural Haiti, approximately 50% of people experi-
encing an ADLA episode sought treatment from health
clinics, traditional healers, or by self-treating [44]. In rural
Ghana, Gyapong et al. found that 55% of those suffering
ADLA episodes sought care (with only 1% going to gov-
ernment health facilities), compared to 88% of those with
other febrile illnesses. Because of distance to health facili-
ties, difficult terrain, and the pain associated with ADLA,
many patients do not seek treatment outside the home
until the episode is almost over [61,74]. In addition,
many patients believe that ADLA is not preventable, since
it recurs even with treatment, so they stop seeking treat-
ment [60,63,74,75]. Data from Togo confirm this impres-
sion, and indicate that many patients have sought help in
the past for ADLA from a wide variety of sources, but cur-
rently either self-medicate or do not seek help [49]. Tradi-
tional practices for ADLA include herbal preparations
which are smeared on the affected limb, scarification or
cutting the skin, and analgesics bought from local drug
peddlers [61,72,75,76].
Treatment and prevention
Treatment
Treatment recommendations for ADLA include rest, cool-
ing the affected area to relieve pain and limit thermal-
related damage to the skin, analgesics and antipyretics to
relieve pain and fever, systemic antibiotics, and elevation
of the affected limb [27,36]. Little is known about the
degree to which antibiotics shorten the duration of ADLA
episodes, but as with erysipelas and cellulitis in areas not
endemic for lymphatic filariasis [38], antibiotic treatment
is recommended [36,37].
Prevention
Basic lymphoedema management. An increasing number of
studies have documented the effectiveness of basic lym-
phoedema management, as recommended by WHO, in
reducing the incidence of ADLA episodes
[47,64,77][78,79]. In Guyana, McPherson found that 10
of 11 patients had reported ADLA during the six months
preceding enrolment in a hygiene education programme,
compared to none of them during the six months after
enrolment [78]. A recent evaluation by WHO reported
dramatic reductions in incidence of ADLA in Sri Lanka,
Zanzibar (United Republic of Tanzania), and Madagascar
[77]. In India, several placebo-controlled studies have
observed significant decreases in ADLA incidence among
lymphoedema patients who only received instruction in
foot care [30,55,56].  Filaria Journal 2007, 6:2 http://www.filariajournal.com/content/6/1/2
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Reductions in ADLA frequency can be maintained for sev-
eral years through home-based care.  In Haiti, the reported
incidence of ADLA during the year before beginning treat-
ment was 2.1 episodes per year; this decreased to 0.6 epi-
sodes after hygiene and skin care were emphasized [47]. A
follow-up assessment 18 months after the patients ‘gradu-
ated’ from clinic visits, but continued lymphoedema care
at home, showed an annual incidence of 0.5 ADLA epi-
sodes per year [53]. Suma and colleagues reported sus-
tained practice of self-care among patients in an area
endemic for brugian filariasis; some two years after
patients had received ‘foot care’ education, 95.3%
reported having fewer or less severe ADLA episodes, with
a mean incidence of 2.8 acute attacks per year [32].  
Prophylactic antibiotics. For patients who continue to expe-
rience frequent episodes of ADLA despite basic measures
of hygiene and skin care, prophylactic antibiotics are rec-
ommended [36]. This practice is also recommended in
non-endemic countries for patients with lymphoedema
who have recurrent cellulitis. The effectiveness of prophy-
lactic antibiotics has been evaluated in several studies.
Olszewski examined the effect of benzathine penicillin,
given at three-week intervals for one year, on the inci-
dence of ADLA, and reported a dramatic decrease, with
recurrent episodes occurring only in 9% of patients [14].
In a placebo-controlled trial in Vellore, India, lym-
phoedema patients who received prophylactic penicillin
experienced greater decreases in ADLA incidence than
those who only received training in foot care [30]. How-
ever, in similar studies in Kerala, India, Shenoy and col-
leagues found that, for most patients, antibiotics provided
little additional benefit if foot care was regularly practiced
[26,55,56]. Kerketta and colleagues, in Orissa, India,
observed lower rates of ADLA among patients who were
randomized to receive foot care and penicillin prophy-
laxis than among patients not receiving penicillin,
although the difference was not statistically significant
[79]. A recent Cochrane review concluded that although
penicillin and foot care appear to reduce the frequency of
cellulitis, further studies are needed to document the
effectiveness of these measures [80].  
Antibiotic soap. An unpublished study from Haiti found
that the incidence of ADLA in lymphoedema patients
decreased to a similar extent (from 1.1 episodes to 0.4 epi-
sodes per year) in patients who washed with antimicro-
bial soap and those who received standard soap [58],
suggesting that hygiene itself was more important than
the antimicrobial content of the soap.    
Participation in patient support groups. Participation in
patient support groups has been shown to decrease the
number of ADLA episodes and improve quality of life
among lymphoedema patients in Haiti [81].  
Risk of death. Fatal outcomes for ADLA are thought to be
uncommon, but most programme managers and clini-
cians who care for patients with lymphoedema are aware
of at least a few cases in which ADLA progressed to septi-
caemia and death. The actual incidence of fatal outcomes
with ADLA is unknown, and risk factors for severe or fatal
ADLA are poorly characterized.  The clinical experience of
Dreyer and others indicates that elderly patients, alcohol-
ics, and patients with malnutrition, hypertension, diabe-
tes, or chronic cardiac or pulmonary disease may be at
increased risk of severe ADLA [36].  
Acute filarial lymphangitis
Pathogenesis
As noted above, among persons born and raised in areas
endemic for bancroftian filariasis, episodes of AFL, due to
death of the adult worm or 4th-stage larva, are less severe
and have less systemic involvement than ADLA. Systemic
involvement may be greater in 'immune-naïve' immi-
grants to endemic areas. Classical AFL was described
extensively in US and European soldiers during World
War II [11,82-85]. AFL is commonly observed following
individual or mass treatment with DEC [86,87], and this
is considered evidence of the drug's macrofilaricidal effi-
cacy [88-90].
Treatment
Treatment of AFL is supportive. Cold compresses, rest,
and analgesics are recommended. Treatment with anti-
filarial drugs during acute inflammatory episodes used to
be recommended, but now is not considered indicated
[27,36,91].
Acute filarial lymphangitis and clinical disease
The degree to which AFL triggers or hastens the develop-
ment of hydrocele in bancroftian filariasis has been inves-
tigated by several authors. Norões and colleagues reported
a 22% incidence of acute hydrocele following a single
'scrotal nodule event', whether spontaneous or induced
by DEC [92]. Overall, 5% of men with scrotal nodules
(adult worm death) developed hydrocele that persisted
for 18 months or longer. Similar findings were observed
in Haiti following mass treatment with DEC and albenda-
zole [93]. Hussein and colleagues in Egypt found that 14
of 16 infected men developed detectable fluid in the
tunica vaginalis cavity after treatment with DEC and
albendazole, of whom three developed chronic hydrocele
[94]. It is unclear whether the lifetime risk of acute or
chronic hydrocele is increased by DEC treatment, or
whether the drug merely synchronizes adult worm death
and, therefore, resulting hydrocele.
AFL appears to trigger the onset of lymphoedema less fre-
quently than it does hydrocele, and persistent lym-Filaria Journal 2007, 6:2 http://www.filariajournal.com/content/6/1/2
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phoedema following AFL is unusual in the absence of
other co-factors [5].
Lymphoedema
The literature on lymphoedema in filariasis-endemic
areas suffers from a lack of standardization, terminology,
and agreed-upon criteria for diagnosis and case definition.
Indeed, many authors use the term 'elephantiasis' for all
forms of lymphoedema. Further, even in non-endemic
areas, there is no one system for classifying or staging lym-
phoedema that is universally accepted [95]. The lack of
standardization limits our understanding of the epidemi-
ology, prevalence, and severity of lymphoedema. Further,
the prevalence of co-morbidity, especially venous disease,
associated with lymphoedema in filariasis-endemic areas
is unknown. An urgent need exists for standardization of
terms and common case definitions, and for improved
knowledge about co-morbidity and its effect on recom-
mended treatment practices.
Pathogenesis
The pathogenesis of lymphoedema in filariasis-endemic
areas has been a matter of intense debate. For many years,
it was believed that a shift in antifilarial immunity trig-
gered the onset of lymphoedema, before which time the
asymptomatically infected host was 'in harmony' with the
parasite [96,97]. However, clinical observations and ultra-
sonographic and lymphoscintigraphic examinations
demonstrated that lymphatic vessel dilatation and dys-
function commonly occur in the absence of lym-
phoedema. The molecules or processes that stimulate
lymphatic vessel dilatation, and the mechanisms by
which this process is maintained, are unknown. The clin-
ical model proposed by Dreyer emphasizes that lym-
phoedema in filariasis-endemic areas is a multifactorial
process [4].
Alternative models have been proposed. Epidemiologic
associations between transmission intensity and the prev-
alence of lymphoedema have suggested to some investiga-
tors that third-stage larvae trigger lymphoedema [18,98].
This hypothesis is supported by observations of decreases
in lymphoedema prevalence and severity following mass
treatment with antifilarial drugs [18]. Although such
reductions are not always observed, these findings suggest
that mass drug administration could have therapeutic
benefits on filarial morbidity.
Longitudinal studies showing that asymptomatic micro-
filaraemic persons are less likely than uninfected persons
to develop lymphoedema suggest an immunologic mech-
anism [99]. Recent studies also have suggested a possible
role for Wolbachia in the pathogenesis of lymphoedema
[19,20].
Epidemiology
Globally, an estimated 16 million persons suffer from
lymphoedema in filariasis-endemic areas of the world
[100]. Clinically, so-called filarial lymphoedema is often
indistinguishable from lymphoedema of other causes,
and there is no laboratory marker that proves, at the indi-
vidual level, that the initial (or only) cause of lymphatic
vessel dysfunction was damage associated with adult filar-
ial worms.
The earliest onset of lymphoedema in filariasis-endemic
areas is usually observed around the time of puberty, and
the prevalence increases with age [101-103]. In many
areas where bancroftian filariasis is endemic, lym-
phoedema of the leg is more common in women than in
men [104-106], although this finding is not universal
[103], especially in areas with brugian filariasis [102].
Gyapong and colleagues have reported an association
between the community prevalence of lymphoedema and
that of microfilaraemia [107].
Little is known about what triggers the onset of clinical
lymphoedema in filariasis-endemic areas, or about what
factors cause lymphoedema, once triggered, to persist.
After lymphoedema is established, recurrent episodes of
ADLA are thought to be the major factor associated with
disease progression, although the role of other factors
remains largely unexplored. Scarification of the skin, a tra-
ditional practice in many filariasis-endemic areas, is con-
sidered a risk factor for rapid progression of filarial
elephantiasis because of the increased risk of ADLA [76].
Economic and psychosocial impact
Cost
Costs to patients for lymphoedema treatment, reported as
both per-visit and per-year costs, vary greatly by study. A
study in India reported an average of US$ 0.56 per visit,
more than half a day's wages [62]. A Ghanaian study
reported costs for treatment of chronic disease (both lym-
phoedema and hydrocele) of US$ 0.87 per visit, equiva-
lent to almost one day's wages [61], and greater than costs
incurred by controls with other chronic diseases. In India,
the annual cost for lymphoedema treatment ranges from
US$ 2.17 to US$ 8.70 per person [108,109]. Average treat-
ment costs are often low, in part because many patients
who find potential treatment costs prohibitive either self-
treat or do not seek treatment [109-111].
Productivity
Productivity losses from lymphoedema have been cap-
tured as lost working hours and as changes in individual
output. Lymphoedema patients in India lose 0.55 to 1.61
hours per day in time at work; 11%–31% of workdays are
lost annually [66,109]. These findings are similar to those
of another study of both lymphoedema and hydroceleFilaria Journal 2007, 6:2 http://www.filariajournal.com/content/6/1/2
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patients, which estimated 1.13 hours lost per day, for a
total of 19% of workdays lost per year [108]. In Ghana,
female labour input loss due to lymphoedema was esti-
mated at 1.5% per year, using the average percentage of
lymphoedema patients unable to complete certain activi-
ties and the local prevalence of lymphoedema [61]. In
general, many patients report changing to less strenuous
occupations or giving up working altogether due to lym-
phoedema and ADLA [69,72,75,112]. A study of male
weavers in India with chronic disease, 26% of whom had
lymphoedema, found a 27% decrease in output com-
pared to controls [113].
Quality of life
Several studies have quantified the impact of lym-
phoedema on quality of life using standardized measures
[44,69,70,73,78,114,115]. McPherson, using a 30-point
Dermatology Quality of Life Index in Guyana, found a
mean baseline score for lymphoedema patients of 10.9
(comparable to patients with psoriasis and atopic eczema
in the United Kingdom), with controls scoring 0.5 [83].
Six months after starting regular hygiene treatment, the
scores improved significantly by an average of 6.8 points
[122]. In Haiti, Kanda compared different ways of meas-
uring quality of life among rural people with lym-
phoedema [46]. Using the EuroQol scale, he found that
no respondents had extreme problems in mobility or self-
care, but more than half reported pain or discomfort. On
a depression scale, the CES-D, these same patients had a
mean score of 13.2 (16 and above indicates depression).
On the CDC Healthy Days questionnaire, Kanda found
that 88% of patients ranked their health as fair or better;
however, they also reported an average of 9.9 physically or
mentally unhealthy days during the past month.
Advanced age, advanced stage of illness, and low educa-
tional level were strongly associated with lower quality-of-
life measures [44]. In India, patients with lymphoedema
scored from 9.2 to 12.4 on a 28-point scale of 'health state
severity' using an extended EuroQol measuring system
[69]. Severity was associated with stage of lymphoedema;
in higher stages, 'severe or very severe problems' were
reported for the domains of usual activities, pain, anxiety/
depression, cognition and social participation. Among
men, the severity score for lymphoedema was signifi-
cantly higher than that for hydrocele [70].
Stigma
Many studies mention the stigma surrounding lym-
phoedema, but they differ in the severity of stigma
reported. Diminished marriage prospects and/or threat of
divorce due to diminished economic productivity and
attractiveness are often cited as problems for persons with
lymphoedema, both by the patients themselves and by
other community members [65,69-75], [116-119]. This
effect appears to be dependent on age of lymphoedema
onset and disease stage [71]. In Haiti, patients reported
that their children had the most difficulty coping, as they
were often teased or embarrassed about the mothers' lym-
phoedema [71]. Following a series of 'soap opera' radio
broadcasts in Haiti, which were intended to decrease
social stigma associated with lymphoedema, patients
reported improved self-efficacy and social support [120].
Impact on activities
A study in Ghana, which did not distinguish between lym-
phoedema and hydrocele, found that those with chronic
filariasis were significantly less likely to be able to perform
market and building activities than matched controls
[61]. Among patients in India who were visited at home
during the course of a year, those with chronic filarial dis-
ease were found to be totally incapacitated at 22% of vis-
its, compared to 13.4% for controls, a significant
difference [108]. Another study in India found that lym-
phoedema patients reported a negative impact on domes-
tic activities (15%–33% of patients), economic activities
(65%–83%), and movement (67%–78%) [121]. Lym-
phoedema patients in Haiti reported decreased ability to
walk, difficulty in finding appropriate footwear, and
sometimes inability to sell at the market or do household
chores [71]. Among those practicing lymphoedema self-
care, 25% stated that lymphoedema limited their ability
to work [53].
Emotional impact
Among filariasis clinic patients in Sri Lanka, 18% felt they
were being shunned by society, although these data were
collected after the patients had been enrolled in treatment
[64]. In other studies, almost all patients report negative
feelings of frustration, isolation, or embarrassment result-
ing from their condition or their inability to find effective
treatment [53,71-74,116,120,122,123]. As lymphoedema
progresses, the negative emotional and psychological
impact often worsens. Patients in an Indian study
expressed suicidal thoughts [69] and depression was com-
mon among patients in Haiti and Togo [44,49]. Anecdotal
reports from other filariasis-endemic countries suggest
that suicidal ideation and depression are not uncommon
among persons with lymphoedema.
Social support
A study in Haiti of patients enrolled in a lymphoedema
treatment clinic found that the odds of regularly practic-
ing hygiene and skin care were 3.7 times greater among
patients who believed that family members supported
them than among those who didn't mention family mem-
ber support [120]. Participation in patient support groups
was shown to decrease the number of ADLA episodes and
improve quality of life among lymphoedema patients in
Haiti [81]. In Brazil, patient 'Hope Clubs' have been
developed to provide ongoing opportunities for socialFilaria Journal 2007, 6:2 http://www.filariajournal.com/content/6/1/2
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and emotional support, problem-solving, and continued
learning [124].
Health-seeking behaviour
Studies in India and Ghana show that 46%–100% of per-
sons with lymphoedema sought treatment from health
care centres, local healers, or pharmacies during the previ-
ous year [61,62,108,109]. The studies in Ghana show that
modern medical care often is avoided due to lack of inter-
est from health care workers and a belief by patients that
lymphoedema treatment requires spiritual interventions
[74,118]. Although many patients believe lymphoedema
progression cannot be prevented, they continue to consult
spiritualists and treat themselves with herbal preparations
or analgesics [75]. In contrast, in areas of India with net-
works of public healthcare facilities, most patients seek
care from modern medical practitioners, although a
minority consult Ayurvedic doctors or use home remedies
first [72,111]. Access to care is not necessarily universal,
however; young women in India may not seek treatment
because of social constraints, such as the paucity of female
doctors [116]. Other barriers to care include distance to a
health facility, lack of awareness, lack of time, lack of child
care, perceived severity of disease, and dissatisfaction with
previous treatment [74,116,122,123]. Even when patients
seek treatment, health personnel often will prescribe anti-
filarial or other drugs that are expensive and ineffective.
Inadequate knowledge of lymphoedema management by
health workers results in suboptimal patient care
[105,111,123,125,126].
Beliefs and traditional practices
Beliefs about the cause of lymphoedema include heredity,
supernatural and spiritual causes, and natural causes such
as injury, standing in cold water, stepping on insects, and
ingesting unhygienic food or drinks
[52,71,74,75,110,116,119,122,127-131].
In filariasis-endemic areas, people with lymphoedema
seek help from traditional healers, herbalists, sorcerers,
and pharmacies, or they self-treat. Traditional treatment
for lymphoedema includes herbal preparations, burial of
the leg, scrubbing the surface of the foot with ants, blood-
letting, and scarification, among others
[71,74,76,110,119,122]. Even in areas with established
clinics for lymphoedema management, where patients
have learned the importance of hygiene, skin care, eleva-
tion and proper footwear, many still hope for a perma-
nent cure [64,71,120,132] (B. Person, personal
communication).
Treatment and prevention
Recognition of the importance of ADLA in the progression
of lymphoedema has led to basic recommendations for
the treatment of lymphoedema in filariasis-endemic
areas. The cornerstones of this treatment include hygiene,
skin care (early detection, treatment, and prevention of
entry lesions), exercise, and elevation of the affected limb
[27,36,133]. In addition to the above measures, appropri-
ate footwear is recommended, and prophylactic antibiot-
ics are recommended for some patients.
All of these recommendations are consistent with proper
lymphoedema care in developed countries where lym-
phatic filariasis is not endemic [134,135]. However, in
these areas, additional modalities are also used, including
compressive bandages, compressive garments, and man-
ual lymphatic drainage [134-137]. These and other meas-
ures would no doubt be helpful for individual patients in
filariasis-endemic areas [133], but require more training,
experience, and resources, and are therefore not included
in the public health approach to managing lymphoedema
adopted by the GPELF for filariasis-endemic countries
[37].
Effectiveness of treatment on acute dermatolymphangioadenitis
Relatively few studies have documented the effectiveness
or impact of the basic package of lymphoedema manage-
ment, and most of these have focused on ADLA. The avail-
able data indicate that such treatment is associated with a
marked reduction in incidence of ADLA
[30,32,47,55,56,58,78]. An unpublished study from Haiti
reported that risk factors for continued ADLA include
more advanced disease, 'negligence', and illiteracy [47].
Effectiveness of treatment on leg volume
A few studies have documented changes in leg volume or
circumference in response to basic lymphoedema man-
agement. Although an 'objective' measurement, leg vol-
ume can vary considerably with time of day, exercise,
elevation, and other factors. In Orissa, India, Kerketta and
colleagues reported significant reductions in leg circum-
ference with all treatment regimens that included basic
foot care [79]. Pani and colleagues reported greater vol-
ume reductions in patients with oedema of recent onset
than in those with lymphoedema of longer duration [51].
An unpublished study from Haiti, which initially
included compressive bandaging as one of its modalities,
reported that more than 65% of 178 patients had a reduc-
tion in leg volume after two years when compared with
pre-treatment measurements [47].
Effectiveness of treatment on entry lesions
It is commonly observed that, with basic lymphoedema
management, the prevalence and severity of entry lesions
decrease [36].
Effectiveness of treatment on odour
Reduction in offensive odour is commonly observed with
regular hygiene. To our knowledge, there have been noFilaria Journal 2007, 6:2 http://www.filariajournal.com/content/6/1/2
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studies focusing on reduction in odour as an outcome of
lymphoedema treatment in filariasis-endemic areas,
although anecdotally this improvement has an important
effect on quality of life.
Effectiveness of treatment on stage of lymphoedema
Few studies have attempted to address the degree to which
basic lymphoedema management results in regression of
lymphoedema stage or grade. In part, this is because most
staging systems have not been developed for this purpose.
Thus, considerable improvement in skin condition or
even leg volume is possible without regression in stage per
se.
Effectiveness of treatment on limb flexibility and range of motion
Improved flexibility and a feeling of 'lightness' are com-
monly reported by patients, but few studies have docu-
mented the effectiveness of basic lymphoedema
management on limb range of motion.
Effectiveness of treatment on quality of life
Several studies are currently underway that address the
extent to which basic lymphoedema management in
filariasis-endemic areas improves quality of life. One
study, by McPherson in Guyana, documented highly sig-
nificant improvement in quality of life as measured by the
Dermatology Quality of Life Index [78]. Similar work in
non-endemic areas has shown substantial gains in quality
of life with lymphoedema treatment. Patients who incor-
porate regular lymphoedema management into their
daily routines have reported satisfaction with the results
[53,138].
Effectiveness of treatment on chronic inflammation
A study in Haiti collected skin punch biopsy specimens
from the lymphoedematous legs of 27 patients before and
about 12 months after they initiated basic lymphoedema
management [139]. Follow-up biopsies showed signifi-
cant reductions in perivascular mononuclear infiltrate in
the superficial dermis (41% decrease in prevalence), in
perivascular fibrosis in the deep dermis (58% decrease),
and in periadnexal mononuclear infiltrate (53%
decrease).
Optimization of treatment protocols
Although there is general agreement as to the basic ele-
ments of lymphoedema management within the GPELF,
considerable regional variation exists in the availability of
supplies, including soap, water, and topical skin prepara-
tions (e.g. antiseptics, antifungal and antibacterial
agents). These differences contribute to variation in
approaches used in different regions. For example, in
some countries, macerated interdigital lesions are treated
with Whitfield ointment, an inexpensive antifungal agent,
on the presumption that dermatophytes are the primary
pathogen. In Guyana, McPherson and colleagues
attempted to culture fungi from these lesions and con-
cluded that bacteria probably play a more important role
than fungi [50]. McPherson's observations are consistent
with studies of intertriginous lesions in non-endemic
areas [140,141].
Controlled studies of how best to optimize the effective-
ness of treatment, particularly for skin care, have not been
published. Some investigators have argued for more wide-
spread adoption of breathing exercises to mobilize lymph
fluid, and for emollients to protect and rebuild the skin
barrier function [133]. These are issues that are amenable
to basic, inexpensive clinical trials.
Programmatic challenges
Although there remains some debate about the optimal
package of interventions for basic lymphoedema manage-
ment in filariasis-endemic areas, the benefits of such treat-
ment are generally recognized, and foci of activity in
several countries have demonstrated success. However,
relatively few persons with lymphoedema living in filaria-
sis-endemic areas currently have access to treatment. Thus,
the key programmatic issue is how best to 'scale up' basic
lymphoedema management to state and national levels.
The challenges can be considered in four major categories:
￿ Finding patients and bringing them to treatment (many
are reluctant to seek care as discussed above)
￿ Education of patients and family members on the prin-
ciples and practice of lymphoedema self-care
￿ Encouragement and support to sustain daily self-care
(this support may include improved access to supplies
such as clean water, soap, antiseptics, topical antibacterial
and antifungal agents, and oral antibiotics)
￿ Referral networks for management of ADLA and for
patients with advanced lymphoedema or lymphoedema
complicated by other diseases.
There is general agreement that most patients can manage
their lymphoedema routinely at home, and that this is
preferable and less costly than clinic-based care. WHO has
developed training packages for 'informal caregivers' to
instruct patients on home-based care, and this approach
has been adopted by most programmes. However, numer-
ous key programmatic and operational research questions
remain unanswered for each of the four major pro-
gramme components. For example: 1) although McPher-
son and colleagues have shown that health workers in
Guyana with limited training can reliably stage lym-
phoedema and identify entry lesions [142], the ability of
such workers to recognize or diagnose lymphoedema inFilaria Journal 2007, 6:2 http://www.filariajournal.com/content/6/1/2
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other settings is unknown; 2) the frequency and intensity
of education required for patients to become competent
in lymphoedema self-care has not been evaluated; and 3)
basic requirements for referral care, provider training, and
clinical competency have not been determined. The costs
of treatment need to be better understood, as well as the
benefits. These are areas in urgent need of investigation if
the benefits of lymphoedema management are to reach
those who most need it.
Prevention
Considerable anecdotal evidence suggests that the onset
of chronic lymphoedema is triggered by the first or second
episode of ADLA. Data from a filariasis-endemic area of
Haiti indicate that skin lesions between the toes, which
could provide portals of entry for bacteria, are common in
children, and are significantly more common in those
who test positive for circulating filarial antigenaemia
[143]. Similar findings have been observed in northeast
Brazil (G. Dreyer, personal communication). The degree
to which initial ADLA episodes, and therefore lym-
phoedema, can be prevented through school-based edu-
cation programmes focused on hygiene, skin care, and
recognition and treatment of entry lesions has not been
studied.
Hydrocele
Despite the greater public health burden of male urogeni-
tal disease in lymphatic filariasis, much more attention
has been focused to date on management of lym-
phoedema of the leg. This is beginning to change, as sur-
gery programmes have been launched in several centres.
However, many questions remain about diagnosis, opti-
mal management, and cost and benefits of intervention.
Pathogenesis
In many research papers written during the 1980s and
1990s on the epidemiology or immunology of lymphatic
filariasis, all genital swelling in men was labelled as
'hydrocele'. This was in contrast to detailed, even elegant,
clinical descriptions of male urogenital disease by investi-
gators in earlier decades [144-147]. Dreyer and colleagues
recently emphasized the distinction between lym-
phoedema of the scrotal and penile skin, which has the
same pathogenesis as lymphoedema of the limbs, and
swelling due to increased fluid inside the cavity of the
tunica vaginalis [36]. This fluid, which is usually consid-
ered to be 'hydrocele', actually is comprised of several dis-
tinct entities including true hydrocele, chylocele and
hematochylocele. The term 'filaricele' has been suggested
recently to include all of these manifestations [148].
Norões and colleagues have shown that true filarial
hydrocele is triggered by death of the adult worm, which
produces an inflammatory nodule that occludes the lym-
phatic vessel. In this study, the incidence of acute
hydrocele following a single 'scrotal nodule event',
whether spontaneous or induced by DEC, was 22% [92].
Of these, 24% persist to become chronic. These data are
similar to those of ultrasonographic and clinical studies
from Egypt [94].
Rupture of lymphatic vessels inside the scrotal cavity can
lead to the presence of straw-coloured ('lymphocele') or
milky (chylocele) fluid, sometimes with red blood cells.
Little is known about the relative frequency of these con-
ditions in different filariasis-endemic areas, and tech-
niques and markers to discriminate among them
preoperatively are currently inadequate.
Epidemiology
An estimated 27 million men suffer from fluid accumula-
tion in the tunica vaginalis in areas endemic for bancroft-
ian filariasis [100]. The prevalence of this condition
appears to be strongly associated with intensity of parasite
transmission. Gyapong has documented a robust associa-
tion at the community level between hydrocele preva-
lence and microfilaraemia prevalence in Ghana
[149,150], and this association has been observed else-
where. The prevalence of hydrocele increases with age.
Little is known about the natural history of hydrocele in
filariasis-endemic areas, although increasing (but as yet
largely unpublished) evidence seems to suggest that it is
much more "fluid" (forgive the pun) than previously real-
ized. Recent observations from Brazil, Egypt, and Haiti
indicate that many acute hydroceles resolve spontane-
ously [92-94].
Economic and psychosocial impact
Costs of non-surgical treatment
Patient expenditures for hydrocele treatment are generally
low, as treatment other than surgery is found to be ineffec-
tive and most patients cannot afford to pay for surgery.
Hydrocele patients in India paid from US$ 1.38 to US$
4.29 per year for non-surgical treatment; daily wages in
the areas studied averaged less than US$ 1.00
[62,108,109]. A Ghanaian study found an average of US$
0.87 a year (almost one day's wages) spent for treatment
of chronic filariasis, which included both hydrocele and
lymphoedema – significantly more than was spent by
patients with other chronic diseases [61]. In general, treat-
ment costs are difficult to collect accurately as much of
treatment is paid in-kind or provided by traditional heal-
ers who are members of the extended family.
Costs of hydrocele surgery
Published costs to patients for hydrocele surgery range
from US$ 5 to US$ 60, depending on the country and
source of care. The types of surgery performed and theFilaria Journal 2007, 6:2 http://www.filariajournal.com/content/6/1/2
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parameters of costing are not known for all studies. Ram-
aiah reported costs of US$ 5–14 in government hospitals
and US$ 15–47 in private hospitals in India [109], while
Babu reported costs of US$ 44 in another Indian study
[108]. In Ghana, Gyapong reported surgery costs of US$
30–35 at local hospitals [61,151] and Ahorlu reported
surgery costs of US$ 30–60 for surgery sponsored by non-
governmental organizations (NGOs) [152]. Interestingly,
the patients in Ahorlu's study estimated that surgery
would have cost US$ 75–125 at local hospitals before the
NGO programme was put in place. Ahorlu also reported
other costs associated with surgery, including transport to
hospital and food, estimated by patients at US$ 20–30,
with an average hospital stay of 4–12 days.
Productivity
Early studies on hydrocele differed in their conclusion
about the impact on productivity, and reductions in pro-
ductivity were not quantified [65,117,129,153]. In recent
studies, the effect of hydrocele on productivity has been
quantified in three different ways:
￿ Individual working hours. Studies in India have shown
that hydrocele patients work approximately one hour less
per day than matched controls [66,108,109]. Lu et al. in
the Philippines found that 30% of 22 males interviewed
lost time from work due to hydrocele [154].
￿ Individual output. A study of weavers with chronic filarial
disease in India, 69% of whom had hydrocele, showed
that those with disease produced 27% less cloth than
matched controls [113].
￿ National output. In India, 8% of potential male labour
input was estimated lost due to hydrocele and lym-
phoedema [109] and this loss was valued at US$ 704 mil-
lion per year [67]. In Ghana this figure was similar, with
more than 7% of potential labour lost [61].
There is almost no evidence on the degree to which
hydrocelectomy improves productivity, with only one
study reporting qualitative data [152].
Quality of life
Early studies described the socially unacceptable nature of
hydrocele, but they were vague about the degree of associ-
ated stigma, its consistency across communities and cul-
tures, and the psychosocial burden of hydrocele on those
affected [65,117,122,155]. To date, research has not been
carried out on quality of life in men with hydrocele in
filariasis-endemic areas that would allow for comparison
with other diseases, or with men who do not have
hydrocele.
Stigma
Hydrocele patients report both 'enacted stigma' (teasing,
problems with marrying and divorce) and 'felt stigma'
(ashamed to be part of community activities)
[75,152,155]. However, they often develop coping strate-
gies to deal with the stigma [151]. For example, men with
hydrocele were less likely to admit that they avoided
social events or suffered teasing than were unaffected peo-
ple to report that they ill-treated men with hydrocele. The
severity and visibility of hydrocele, as well as the relation-
ship of patients to community members, seems to corre-
late with the degree of stigma [117]. Gyapong et al.
described general community acceptance of men with
hydrocele, but reported that patients with advanced dis-
ease often feel ostracized and embarrassed [74]. In Kenya,
36% of men with hydrocele interviewed responded that
they were laughed at, while 29%, mostly patients with
small hydrocele, reported no reaction from the commu-
nity [122]. When community members were asked about
their reactions to men with hydrocele, those who had
family members with hydrocele expressed understanding
and sympathy, while others tended to joke about it. In
non-endemic villages in Ghana, considerable stigma was
associated with hydrocele and lymphoedema, much more
than in hyper-endemic villages [118].
Impact on activities
In rural India, 8%–10% of men with hydrocele reported a
negative impact on domestic work, 53%–55% reported a
negative impact on economic activities, and 53%–63%
reported decreased mobility [121]. A study in Ghana
found that 10%–60% of persons with chronic filarial dis-
ease, which included both lymphoedema and hydrocele
patients, were unable to perform certain daily activities
and were less likely to perform market and building activ-
ities than matched controls who had other chronic dis-
eases [61]. Of 14 school-aged boys with hydrocele
interviewed in India, one had dropped out of school as a
result of being stigmatized and six had high rates of absen-
teeism [68]. An Indian study measuring the psychosocial
and physical burden of hydrocele found that patients'
usual activities and social participation were affected by
hydrocele, especially for those with larger hydroceles. In
addition, as noted in earlier studies [69,155], many men
had switched to less demanding occupations as a result of
hydrocele.
Emotional impact
Men with hydrocele often describe themselves as frus-
trated, losing hope and even suicidal [117,151,154,156].
In the Philippines, Lu reported that those in higher socio-
economic classes were less emotionally affected as they
were aware of, and had access to, surgery [154].Filaria Journal 2007, 6:2 http://www.filariajournal.com/content/6/1/2
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Male identity and sexual function
In 1993, the limited literature on hydrocele in filariasis-
endemic areas suggested that hydrocele had little impact
on sexual activity or fertility [117]. More recently,
hydrocele patients in India reported that hydrocele
adversely affected their sexual functioning and caused
'moderate problems' with anxiety/depression, based on
an extended EuroQol scale [69]. In Ghana, both commu-
nity members and men with hydrocele reported that
hydrocele impeded sexual intercourse, sometimes leading
to divorce [75,151]. Qualitative research in Ghana found
that men "whose hydrocele interfered with (this) concept
of male identity were deeply frustrated"; they felt as if they
were a burden to their families because of difficulties in
providing for them [151]. In Brazil, Dreyer and colleagues
reported several concerns of men with urogenital disease,
including genital elephantiasis, which ranged from lack of
intimacy in marriage to thoughts of suicide [156].
Social support
While perceived social support is important for psycho-
logical well-being, we found no published studies that
addressed the impact of hydrocele on patients' social sup-
port networks or the impact of social support networks on
recuperation after surgery.
Health-seeking behaviour
A wide range (25%–80%) of hydrocele patients seek treat-
ment [61,62,109,151]. Patients seek treatment from local
health centres, traditional healers, and through self-medi-
cation. In certain countries, the belief that hydrocele has a
supernatural cause leads people to seek out traditional
healers or sorcerers instead of modern medical care [74].
While most studies describe treatment only during the
previous year, patients may have tried various remedies in
the past but stopped seeking care after the treatments were
ineffective [74,122,151]. Other reasons for not seeking
treatment include problems with access, such as cost of
surgery or medical treatment, distance from the health
centre, inability to take time off work for recovery, and
cultural issues such as fear of anaesthesia during surgery
and stigma associated with having hydrocele
[61,117,152,154,155]. A study in coastal Kenya found
that, in highly endemic districts, hydrocelectomies
accounted for 23% of all major operations [157]. Simi-
larly, in Tanzania in 1976, 15% of operations in one dis-
trict hospital were for hydrocele [158].
Beliefs and traditional practices
Beliefs about the causes of hydrocele vary by culture and
geography, but can be grouped into supernatural causes
(including witchcraft and sorcery), heredity, exposure to
extreme hot or cold, excessive sexuality, and consumption
of certain foods or drinks [74,75,117,122,154]. Some
studies also mention hard work or trauma as the cause of
hydrocele [127,129,152]. Few mention mosquitoes, even
in regions where mass drug administration and health
education have occurred [117,127,131,155,159,160].
Only 2.5% of hydrocele patients in a study in rural South
India believed that filariasis was transmissible [131]. And
the link between filarial infection, hydrocele and lym-
phoedema is often not understood. Only 1%–4% of peo-
ple interviewed in an Indian study knew that filarial
infection was a major cause of hydrocele [161]. In a study
in Orissa, India, while less than half of respondents knew
that mosquitoes contributed to the spread of hydrocele,
about 70% named them as the cause of lymphoedema
[160].
Traditional remedies used to treat hydrocele include
herbal preparations, sorcery spells and rites, and draining
with hollow reeds [74,75,122]. Perceptions of treatment
efficacy vary greatly by region, with a majority of people
naming surgery as a cure [74,75,127,155,160]. However,
90% of persons with lymphoedema and/or hydrocele
interviewed on the Kenyan coast believed their disease
was incurable. This may have been influenced by the expe-
rience of two elderly men in the area who had a recurrence
of hydrocele after surgery [122].
Treatment
Surgery is the recommended intervention for hydrocele,
and if done properly, it is regarded as curative. Other tech-
niques, such as aspiration of the fluid and injection of
sclerosing substances, are less effective, have unacceptable
side effects, and have not been adequately evaluated in
filariasis-endemic areas [147,162]. Recently, Ryan has
called for studies of other measures, such as deep breath-
ing, to reduce the size of hydrocele [163].
A variety of surgical techniques are used for hydrocele in
filariasis-endemic areas, although little is known about
their relative frequency of use. Modifications of the 'ever-
sion' technique are probably most commonly used, in
which part of the tunica vaginalis is excised and the
remainder is everted. While this approach may be effective
for non-filarial hydrocele or for 'pure' hydrocele in filaria-
sis-endemic areas, it is likely sub-optimal as a procedure
for lymphocele or chylocele, because dilated, leak-prone
lymphatic vessels – the source of the excess fluid – may
not be removed. Thus, the risk of recurrence may be sub-
stantial. Eversion techniques have also been associated
with other more serious complications, including devel-
opment of the debilitating condition of lymph scrotum,
for which surgical treatment is vastly more challenging
than that for hydrocele [144]. Thus, current WHO guide-
lines call for complete removal of the tunica vaginalis
[164].Filaria Journal 2007, 6:2 http://www.filariajournal.com/content/6/1/2
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Few studies have been published on the rates of complica-
tions and recurrence following hydrocele surgery in
filariasis-endemic areas. A study from Wardha, India,
reported a 26.7% incidence of wound infection or hae-
matoma in cases considered filarial in aetiology, com-
pared with 10.9% in non-filarial hydrocelectomies [165].
Among 950 surgeries for large hydrocele in Orissa, India,
post-operative infections and abscesses were seen in 28
(2.9%) cases, scrotal haematoma in 12 (1.3%), and
reversible penile oedema in 42 (4.4%) [166]. The paucity
of data on outcomes makes it impossible to compare cost
or effectiveness of one technique over another. Surgical
outcomes are currently being evaluated in several coun-
tries.
Research is urgently needed to 1) evaluate tools to distin-
guish the various forms of 'filaricele' preoperatively; and
2) assess costs, resource requirements (e.g. time, anaesthe-
sia, electricity), surgery duration, post-operative quality of
life, and incidence of relapse and infectious and other
post-operative complications with different surgical tech-
niques.
Impact of hydrocele surgery on quality of life
Ahorlu et al. interviewed hydrocele patients in Ghana 1.5
years after surgery. Patients reported that within three to
six months post-surgery, they had experienced significant
improvement in self esteem, sexual function, and capacity
for work, and they participated more in community activ-
ities [152].
Antifilarial drug treatment and filarial morbidity
Data on the impact of treatment with antifilarial drugs on
filarial morbidity are inconsistent. Several studies have
reported reductions in acute attacks, lymphoedema, and/
or hydrocele following mass drug administration, but
other studies report no such association (Table 2). For
most of these studies, the primary outcome of interest was
microfilaraemia rather than clinical morbidity. Therefore,
the studies are often limited by inadequate or non-stand-
ardized case definitions, inadequate sample sizes, and
intermittent or incomplete follow-up. Many studies have
only evaluated the effect of drug treatment in persons with
existing morbidity. Such an approach ignores the inci-
dence of new cases, and could lead to erroneous conclu-
sions regarding the effect of the antifilarial drugs on
disease incidence or prevalence.
Table 2: Summary of studies that assessed the effect of antifilarial drug treatment on the clinical manifestations of "acute attacks"*, 
hydrocele, and lymphoedema.
Source Acute Attacks* Hydrocele Lymphoedema Drug Drug delivery strategy Follow-up interval
Ciferri 1969 [170] + -- -- DEC MDA 2 years
March 1960 [171] + + + DEC MDA 10 years
Bernhard 2001 [169] . -- . DEC MDA, clinical trial 1 year
Partono 1989 [172] + . + DEC MDA, selective 11 years
Beye 1952 [173] -- -- -- DEC MDA, selective 16 months
Simonsen 1995 [174] . --** . DEC Selective 1 year
Kessel 1957 [175] + . . DEC Selective 1 year
Fan 1995 [176] . -- -- DEC Salt 16–19 years
Meyrowitch 1996 [177] . + + DEC Salt 2 years
Meyrowitch 1998 [178] . + . DEC Salt 4 years
Meyrowitch 2004 [179] . +¶ . DEC MDA, salt 4 years
Hewitt 1950 [180] + +¶ +¶ DEC Clinical trial 8–14 months
Das 2003 [167] . . -- DEC Clinical trial 1 year
Kenney 1949 [181] . . + DEC Clinical trial 1–3 months
Pani 1989 [51] . . +‡ DEC Clinical trial† >1 year
Moore 1996 [16] . . + DEC Case report 1 week-7 months
Bockarie 2002 [18] . + + DEC, DEC+IV MDA 5 years
Dunyo 2000 [182] . -- -- IV + Alb MDA 1 year
* Acute dermatolymphangioadenitis and filarial lymphangitis were not distinguished in most studies
** 2 of 8 hydroceles resolved
¶Disease progression also observed
‡ Reductions seen primarily in patients with early-stage disease
† Included other interventions, but improvement related to number of DEC doses
+ Decrease in size, incidence, or prevalence noted (not necessarily statistically significant)
-- No decrease noted (or if noted, inconsistent or not considered significant by authors)
. Not evaluated or extremely small numbers
DEC Diethylcarbamazine
IV Ivermectin
Alb Albendazole
MDA Mass drug administration using tablets
Salt DEC-fortified salt
Selective Treatment only of persons known to be infected or with clinical diseaseFilaria Journal 2007, 6:2 http://www.filariajournal.com/content/6/1/2
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Clinical studies have also produced inconsistent findings.
A detailed case report of a US Peace Corps volunteer dem-
onstrated dramatic clinical improvement in lym-
phoedema following DEC treatment [16], but a clinical
trial by Das and colleagues in Pondicherry, India found
no change in limb volume or condition [167]. A study
using lymphoscintigraphy in Recife, Brazil found no
improvement in lymphatic morphology among patients
with clinical or subclinical disease following treatment
with DEC [168]. A carefully designed placebo-controlled
study by Bernhard and colleagues found no effect of DEC
treatment (in the context of mass treatment) on hydrocele
volume [169]. As noted above, treatment with DEC can
provoke both acute and chronic hydrocele in men with
W. bancrofti infection [92,93].
Assessing the public health impact of mass treatment with
antifilarial drugs is a critically important issue for pro-
gramme advocacy and for planning morbidity control
strategies. Studies on the impact of antifilarial drugs on
the prevalence and incidence of acute inflammatory epi-
sodes, lymphoedema, and hydrocele are needed, using
rigorous case definitions, close clinical assessment, and
control groups. They should be conducted in areas where
DEC and albendazole are coadministered as well as in
areas where ivermectin and albendazole are used.
Conclusion
Morbidity control efforts within the GPELF have focused
on: 1) basic lymphoedema management (hygiene, skin
care, and simple physical measures) to reduce the inci-
dence of ADLA and prevent progression of lymphoedema;
and 2) surgical repair of hydrocele. Since the GPELF was
launched in 1998, considerable research has documented
the effectiveness of basic lymphoedema management and
provided a stronger scientific base for this intervention.
Less work has been done to document the costs and ben-
efits of hydrocele surgery in filariasis-endemic areas. Addi-
tional research is needed to support efforts to 'scale up'
morbidity control and disability alleviation programmes
at the national level and to document the extent to which
antifilarial drug treatment influences the course of filaria-
sis-associated disease.
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